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TranscriptomicsAmyotrophic lateral sclerosis (ALS) is a rapidly progressive and ultimately fatal neurodegenerative disease,
caused by the loss of motor neurons in the brain and spinal cord. Although 10% of ALS cases are familial
(FALS), the majority are sporadic (SALS) and probably associated to a multifactorial etiology. Currently there is
no cure or prevention for ALS. A prerequisite to formulating therapeutic strategies is gaining understanding of
its etio-pathogenicmechanisms. In this studywe analyzedwhole-genome expression proﬁles of 41motor cortex
samples of control (10) and sporadic ALS (31) patients. Unsupervised hierarchical clusteringwas able to separate
control from SALS patients. In addition, SALS patients were subdivided in two different groups that were associ-
ated to different deregulated pathways and genes, some of which were previously associated to familiar ALS.
These experiments are the ﬁrst to highlight the genomic heterogeneity of sporadic ALS and reveal new clues to
its pathogenesis and potential therapeutic targets.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Amyotrophic lateral sclerosis (ALS) is a fast progressive and dis-
abling neurodegenerative disease characterized by upper and lower
motor neuron loss, leading to respiratory insufﬁciency and death after
3–5 years (Mitchell and Borasio, 2007). The incidence of ALS ranges
from 1.7 to 2.3 cases per 100,000 population per year world-wide
(Beghi et al., 2006). Despite intensive research, knowledge of the path-
ogenetic mechanisms and precise genetic causes of ALS remains incom-
plete. Although most cases of ALS are isolated or sporadic (SALS), about
10% are familial (FALS) and have been linked to the mutation of several
genes (Abel et al., 2012; Andersen and Al-Chalabi, 2011; Lill et al., 2011;
Simpson and Al Chalabi, 2006; Valdmanis and Rouleau, 2008; Yoshida
et al., 2010), such as SOD1 (Rosen, 1993), ALSIN (Hadano et al., 2001),
SETX (Chance et al., 1998; Chen et al., 2004), SPG11 (Orlacchio et al.,
2010), FUS (Kwiatkowski et al., 2009; Vance et al., 2009), VAPB
(Nishimura et al., 2004), ANG (Chen et al., 2010; Greenway et al.,
2006), TARDBP (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan
et al., 2008), Fig. 4 (Chow et al., 2009), OPTN (van Es et al., 2009),
ATXN2 (Elden et al., 2010), and C9ORF72 (DeJesus-Hernandez et al.,iche, CNR, Via Paolo Gaifami, 18,
ro).
ect.com).
. This is an open access article under2011; Renton et al., 2011). Although the etiology of SALS remains largely
unknown, a number of observations suggest a role for genetic factors in
SALS (Andersen and Al-Chalabi, 2011). While FALS genes may account
for some cases of SALS, this is currently viewed as amulti-factorial com-
plex disease, in which multiple genetic variants, each of small effect,
combine with environmental triggers and risk factors (Andersen and
Al-Chalabi, 2011; Armon, 2001; Majoor-Krakauer et al., 2003; Simpson
and Al Chalabi, 2006).
The pathogenic processes underlying ALS are not fully determined.
In the last few years, a number of transcriptome studies in peripheral
cells or postmortem nervous tissue of ALS patients have started to deci-
pher genes and pathways involved in disease pathogenesis (Cox et al.,
2010; Dangond et al., 2004; Jiang et al., 2005; Lederer et al., 2007;
Malaspina et al., 2001; Offen et al., 2009; Rabin et al., 2010; Wang
et al., 2006). Although comparison of results is often difﬁcult, because
of different tissues and/or microarray platforms, common alterations
implicated by these transcriptome studies were related to the cytoskel-
eton, inﬂammation, protein turnover and RNA splicing (Saris et al.,
2013). Due to the inherent complexity of nervous tissue and the need
for postmortem material, however, the existing genomics studies of
ALS were restricted to a limited number of postmortem ALS samples
(≤11 motor cortex, and 14 spinal cord) (Cox et al., 2010; Dangond
et al., 2004; Jiang et al., 2005; Lederer et al., 2007; Malaspina et al.,
2001; Offen et al., 2009; Rabin et al., 2010;Wang et al., 2006). To uncov-
er the entire spectrumof genes and pathways involved in ALS pathologythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
360 E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376we analyzed whole-genome expression proﬁles of motor cortex sam-
ples from control (10) and SALS (31) patients (Table 1). By unsuper-
vised hierarchical clustering we separate control from ALS patients,
and subdivide the latter in two different groups that are associated to
differentially expressed genes and pathways.
Materials and methods
Characteristics of subjects
Two groups of patient samples were used in this study: 31 motor
cortex from SALS patients, and 10 motor cortex from control individ-
uals. Fresh-frozen samples were obtained from the department of Pa-
thology of the Academic Medical Center (University of Amsterdam)
and selected for post-mortem intervals (PMI) prior to freezing not ex-
ceeding 24 h (mean PMI: 7.07 h for controls and 6.62 h for SALS). All
SALS patients (meanpatient age of 57) fulﬁlled the El Escorial diagnostic
criteria (Brooks et al., 2000) and underwent genetic screening for genes
associated to ALS. Diagnosis was independently conﬁrmed by two neu-
ropathologists according to standard histopathological criteria (Ince
et al., 1998; Piao et al., 2003). The control samples (mean patient age
of 55 years) were obtained from patients who had died from a non-Table 1
Characteristics of subjects.
Patient code Race Gender Age PMI (hours)
1 Caucasian Male 31 8
2 Caucasian Male 59 7
3 Caucasian Male 68 8
4 Caucasian Female 71 9
5 Caucasian Male 48 4
6 Caucasian Male 58 7
7 Caucasian Male 60 6.5
8 Caucasian Male 44 9
9 Caucasian Male 73 10
10 Caucasian Male 39 8
11 Caucasian Male 67 8
12 Caucasian Male 41 10
13 Caucasian Male 65 6.5
14 Caucasian Male 68 6
15 Caucasian Female 67 8
16 Caucasian Male 43 6
17 Caucasian Male 54 3
18 Caucasian Male 38 7
19 Caucasian Male 45 6.5
20 Caucasian Female 46 7
21 Caucasian Female 65 7
22 Caucasian Male 54 8
23 Caucasian Male 51 4
24 Caucasian Male 69 10
25 Caucasian Male 68 7
26 Caucasian Female 68 8
27 Caucasian Male 61 3
28 Caucasian Female 57 4
29 Caucasian Female 40 5
30 Caucasian Male 41 3
31 Caucasian Female 61 6
32 Caucasian Female 61 10
33 Caucasian Female 51 7
34 Caucasian Male 63 7.5
35 Caucasian Female 70 4
36 Caucasian Female 69 9
37 Caucasian Female 64 5.3
38 Caucasian Male 46 7.5
39 Caucasian Male 55 6
40 Caucasian Male 51 8
41 Caucasian Male 59 8
Fresh-frozenmotor cortex samples were obtained from the Department of Neuropathology of
died from a non-neurological disease (myocardial infarction, renal failure, or pulmonary emb
formed consent was obtained for the use of brain tissue and for access to medical records for
research.neurological disease (cause of death: myocardial infarction, renal fail-
ure, pulmonary embolism). Both ALS and control patients included in
the study displayed no signs of infection before death. Informed consent
was obtained for theuse of brain tissue and for access tomedical records
for research purposes and approval was obtained from the relevant
local ethical committees for medical research.
Detailed information related to origin, source code, age, gender, race,
disease state, survival time from diagnosis date and PMI of patient sam-
ples is given in Table 1.
Sample preparation
Individual slices of 10 μm were produced from tissue samples at
−20 °C by a Leica CM1510S cryostat (Leica Microsystems) and stored
at−80 °C until further processing. Two slices per sample were stained
by hematoxylin/eosin staining (Bio Optica) and for Nissl substance
(with a microﬁltered solution of cresyl violet, Sigma-Aldrich), respec-
tively, to assess integrity of cellular and tissuemorphology. Ten adjacent
slices per sample were pooled and used for RNA extraction with Trizol
(Life Technologies) RNA integrity was conﬁrmed by using a RNA chip
and a 2100 Bioanalyzer (Agilent Technologies, Italy) with the protocol
outlined by the manufacturer.Disease state Survival time from
diagnosis date (months)
Unsupervised cluster
Control n/a Control
Control n/a Control
Control n/a Control
Control n/a Control
Control n/a Control
Control n/a Control
Control n/a Control
Control n/a SALS 1
Control n/a SALS 2
Control n/a SALS 2
SALS 90 SALS 1
SALS 96 SALS 1
SALS 38 SALS 1
SALS 30 SALS 1
SALS 27 SALS 1
SALS 38 SALS 1
SALS 31 SALS 1
SALS 42 SALS 1
SALS 38 SALS 1
SALS 31 SALS 1
SALS 52 SALS 1
SALS 49 SALS 1
SALS 60 SALS 1
SALS 20 SALS 1
SALS 18 SALS 1
SALS 22 SALS 1
SALS 11 SALS 1
SALS 7 SALS 1
SALS 130 SALS 2
SALS 72 SALS 2
SALS 43 SALS 2
SALS 29 SALS 2
SALS 29 SALS 2
SALS 27 SALS 2
SALS 30 SALS 2
SALS 52 SALS 2
SALS 71 SALS 2
SALS 48 SALS 2
SALS 18 SALS 2
SALS 23 SALS 2
SALS 13 SALS 2
the Academic Medical Center, University of Amsterdam, The Netherlands. Control patients
olism). All patients included in the study displayed no signs of infection before death. In-
research purposes, approval was obtained from the local ethical committees for medical
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Complementary RNAs (cRNAs) labeled with Cy3-CTP (Perkin-Elmer)
were synthesized from 1 μg of total RNA of each sample using the Low
RNA Input Fluorescent Linear Ampliﬁcation Kit (Agilent Technologies)
following the manufacturer's protocol. Aliquots (750 ng) of Cy3 labeled
cRNA targets were co-hybridized on 4x44K Whole Human Genome
OligoMicroarrays (Agilent Technologies, Italy). Microarray hybridization
and washing were performed using reagents and instruments (hybridi-
zation chambers and rotating oven) as indicated by the manufacturer
(Agilent Technologies). Microarrays were scanned at 5-μm resolution
using a GenePix Personal 4100A microarray scanner and the GenePix
Pro 6.0 acquisition and data-extraction software (Molecular Devices,
Corp.). Quality control analysis on all samples and parameters associated
(Table 1) was performed using GeneSpringGX v.12.6.1 (Agilent Technol-
ogies, Italy). Raw signal values were thresholded to 1, log2 transformed,
normalized to the 50th percentile, and baselined to the median of all
samples using GeneSpringGX v.12.6.1 (Agilent Technologies, Italy).
Genes with a corrected P value b 0.05 (one-way ANOVA followed by
the Benjamini and Hochberg False Discovery Rate and the Tukey's Post
Hoc test) were considered differentially expressed.
To analyze gene expression changes in the context of known biolog-
ical pathways we used MetaCore (Nikolsky et al., 2005). P values were
calculated using a basic formula for hypergeometric distribution
where the P value essentially represents the probability of particular
pathway arising by chance. To limit possible number of type I errors
among the test results a False Discovery Rate (FDR) threshold of 0.05
was used to identify statistically signiﬁcant pathways.
Raw data of the microarrays are available at ArrayExpress
(http://www.ebi.ac.uk/arrayexpress/) with the accession number
E-MTAB-2325.Quantitative RT-PCR
To further conﬁrm the reliability of the microarray data, the mRNA
levels of ten differentially expressed genes (ANXA2, AQP1, ATP1A3,
HMOX2, HPRT1, NGFR, NRGN, OLFM1, SERPINA3, VIP) were quantiﬁed
by real-time quantitative RT-PCR. Genes were randomly selected by
crossing differentially expressed genes with RT-PCR primers available
in our repository. Aliquots of cDNA (0.1 and 0.2 μg) from individual
samples, and known amounts of external standards (puriﬁed PCR prod-
uct, 102 to 108 copies)were ampliﬁed in parallel reactions using primers
shown in Table 2. PCR ampliﬁcations were performed as previously de-
scribed (Lederer et al., 2007). Speciﬁcity of PCR products obtained was
characterized bymelting curve analysis followed by gel electrophoresis
and DNA sequencing.Table 2
Conﬁrmation of microarray data by real time RT-PCR.
Fold change ALS1/Control ALS2/Control P-value Mic
pro
Gene symbol Microarray RT-PCR Microarray RT-PCR Microarray RT-PCR
NGFR −1.41 −1.50 2.68 * 3.42 8.27E−04 0.033 A_2
ATP1A3 2.44 * 3.66 −1.05 −1.38 9.36E−03 0.002 A_2
HPRT1 1.23 1.49 −2.46 * −2.27 2.48E−04 0.013 A_2
NRGN 1.70 2.10 −3.86 * −3.56 4.02E−04 0.027 A_2
HMOX2 1.77 2.11 −3.22 * −4.41 3.42E−05 0.034 A_2
OLFM1 1.50 1.38 −3.90 * −3.47 4.61E−05 0.041 A_2
SERPINA3 13.40 * 11.03 3.07 * 4.35 1.88E−05* 0.008 A_2
VIP 1.11 1.41 −2.51 * −3.12 1.66E−03 0.015 A_2
AQP1 3.84 * 4.28 −1.56 −1.48 9.88E−05 0.022 A_2
ANXA2 3.17 2.87 1.17 1.07 3.38E−05 0.032 A_2
Pearson coeff. 0.98 0.99
Signiﬁcant P-values refers to pairwise comparisons indicated by *.Immunohistochemistry
Parafﬁn-embedded tissue was sectioned at 6 μm and mounted on
pre-coated glass slides (StarFrost, Waldemar Knittel Glasbearbeitungs
GmbH, Braunschweig, Germany). Representative sections of all speci-
mens were processed for hematoxylin and eosin, Klüver-Barrera and
Nissl stains. Antibodies against SERPINA3,major histocompatibility com-
plex (MHC) class I (HLA A, B and C;mouse clone HC-10; 1:200; gift from
Prof. J. Neefjes, NKI, The Netherlands), and MHC class II (HL-DR; mouse
clone CR3/43; 1:400; DAKO, Glostrup, Denmark) were used for
imunohistochemical analysis of ALS specimens. Target selection was
based on the encoding genes strongly and differentially regulated, and
on the availability of commercial antibodies that could be used on
human formalin ﬁxed parafﬁn embedded material. Single-label immu-
nohistochemistry was performed as previously described (Aronica
et al., 2003; Aronica et al., 2001) with the Powervision kit (Immunologic,
Duiven, The Netherlands) and 3,3-diaminobenzidine as chromogen. The
intensity of HLA-ABC, HLA-DR and serpina3 immunoreactive stainings
was evaluated using a scale of 0–3 (0: no; 1: weak; 2: moderate; 3:
strong staining). All areas of the stained specimen were examined and
the score represents the predominant cell staining intensity found for
each case. The frequency of positive cells (microglia/astrocytes) was
also evaluated and scored (1: rare; 2: sparse; 3: high) to inform on the
relative number of positive cells within the hippocampus. As proposed
before (Aronica et al., 2005; Iyer et al., 2010), the product of these two
values (intensity and frequency scores) was taken to give the overall
score (total labeling score). Evaluation of albumin IR (extravasation,
with uptake in astrocytes) was also performed.Results
Patient segregation by unsupervised hierarchical clustering
By using oligonucleotide microarrays we monitored mRNA expres-
sion proﬁles of 41,059 genes in motor cortex control (10) and SALS
(31) patients (Table 1). An unsupervised, hierarchical clustering algo-
rithm allowed us to cluster the 41 motor cortex samples on the basis
of their similarities measured over the most informative genes (9646
genes with a standard deviation N1.5; Supplementary Table 1). Similar-
ly, the same genes were clustered on the basis of their similarities mea-
sured over the group of 41 motor cortex samples. The transcriptomic
proﬁles obtained in cortex samples produced a good separation of con-
trols and SALS patients, segregating these latter into two distinct groups
(Fig. 1a). Control patients were mainly (7/10) grouped in a single clus-
ter, whereas SALS patients segregated into cluster 1 (18/31) and cluster
2 (13/31). Thus, using unsupervised clustering we can distinguishroarray
be ID
Forward primer Reverse primer
3_P389897 CGGCTACTACCAGGATGAGA GTGCTGGCTATGAGGTCTTG
3_P27472 TCAAGAAGGAGGTGGCTATG GAGAAGCAGCCAGTGATGAT
3_P11372 CCTGCTGGATTACATTAAAGCACTG CCTGAAGTACTCATTATAGTCAAGG
3_P116264 GACTAGGCCAGAACTGAGCA AGTGGCACGGAGATGTAGG
3_P100501 TCGTCTGACAGCATCCTCTC GTGTGGAAGCCTGGAGTAGA
4_P406601 ATTAGGAGGCGAGGAGAGAG GATGAGGAAGAGGAGGCTGA
3_P2920 CTGGCTGATGGTGTGAACTC GCCAGGATGAAGTCGTAGAT
3_P19650 TCCTTGTGCTCCTGACTCTT AAGACTGCATCTGAGTGACG
3_P372834 GACACCTCCTGGCTATTGAC TAAGAGGCTTGACCATGCAG
3_P146644 GATCATCTGCTCCAGAACCA GAGTCATACAGCCGATCAGC
Fig. 1. Panel a. Unsupervised hierarchical clustering of control and SALS patients. Unsupervised hierarchical clustering (similarity measure: Pearson centered; linkage rule: average) was
used to cluster control and SALS patients on the basis of their similarities measured over the most informative genes expressed in motor cortex (9646 genes with a standard deviation
N1.5). Similarly, the same genes were clustered on the basis of their similarities measured over the motor cortex of control and SALS patients. In this two-dimensional presentation,
each row represents a single gene and each column a motor cortex from control or SALS patients. As shown in the color bar, red indicates up-regulation, green down-regulation, black
no change. In the dendrograms shown (left and top), the length and the subdivision of the branches display the relatedness of the expression of the genes (left) and the motor cortex
(top). Although SALS patients could be clearly distinguished on the basis of their motor cortex gene expression patterns, no signiﬁcant association was found between their clinical char-
acteristics and cluster assignment. In addition to the clinical characteristics listed in Table 1, our analysis included location of onset (arm, trunk, leg), occupation, the use of smoke or al-
cohol, the presence of other pathological conditions, therapy used, vaccinations, and family anamnesis (data not shown). Panel b. Venndiagrams of differentially expressed genes inmotor
cortex of control and SALS (clusters 1 and 2) patients (Supplementary Tables 2–4). Panel c. Hierarchical clustering of differentially expressed genes in motor cortex of control SALS1 and
SALS2 patients. Genes are arranged in a hierarchical cluster based on their expression patterns, combined with a dendrograms (left) whose branch lengths reﬂect the relatedness of ex-
pression patterns. As shown in the color bar, red indicates up-regulation, green down-regulation, black no change.
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363E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376control from SALS patients, and separate SALS patients in two greatly di-
vergent groups. Patient stratiﬁcation in these groups by unsupervised
hierarchical clusteringwas not related to technical variation (arrays hy-
bridization) or patient demographic (gender, age at onset, age at death,
survival time from date of onset, PMI) (Supplementary Fig. 1).
Differentially expressed genes in motor cortex of control and SALS patients
When gene expression proﬁles in SALS1 and SALS2 were compared
to controls, 4485 and 16,144 genes showed signiﬁcant changes of gene
expression, respectively (Fig. 1b) (Supplementary Tables 2–4). Al-
though some of these genes (1268) were differentially expressed in
both pairwise comparisons, the majority of differentially expressed
geneswere cluster speciﬁc. A larger number of genes (21,930) were dif-
ferentially expressed between SALS1 and SALS2, indicating these clus-
ters were greatly divergent at the genomic level. A comprehensive
picture of transcriptional changes associated to these three clusters is
shown in Fig. 1c where differentially expressed genes are grouped on
the basis of similarity in their expression patterns in different patients
with a hierarchical clustering method.
Conﬁrmation by quantitative RT-PCR
To conﬁrm the reliability of the array data,we quantitatively validat-
ed the differential expression of ten genes (ANXA2, AQP1, ATP1A3,
HMOX2, HPRT1, NGFR, NRGN, OLFM1, SERPINA3, VIP) using real-time
quantitative reverse transcription-polymerase chain reaction (RT-PCR)
(Table 2).
Remarkably, the pattern of gene expression observed bymicroarrays
precisely paralleled the pattern observed using real-time RT-PCR (cor-
relation coefﬁcient r = 0.98), conﬁrming the up-regulation or down-
regulation of these genes in the SALS motor cortex.
Conﬁrmation by immunohistochemistry
To validate our ﬁndings for mRNAs at the protein level we per-
formed immunohistochemistry analysis of SERPINA3, MHC class I
(HLA-ABC) and II (HLA-DR) in motor cortex samples of control, SALS1
and SALS2 patients. In addition to showing a signiﬁcant correlation be-
tween mRNA and protein levels, our analysis allowed to distinguish
their cellular localization (Fig. 2 and Supplementary Fig. 1). Increased
expression of SERPINA3 immunoreactivity was observed in reactive as-
trocytes of SALS1 patients. In control and SALS2 patients, MHC class I
(HLA-ABC) immunoreactivity was mainly detected in endothelial cells,
whereas an increased expression in SALS1 patients was observed in ac-
tivated microglial cells. In control and SALS2 patients, MHC class II
(HLA-DR) immunoreactivitywas detected in cells of themicroglia/mac-
rophage lineage (weak expression in resting microglial cells), whereas
in SALS1 patients an increased expression was observed in activated
microglial cells.
Deregulated pathways in motor cortex of SALS patients
To identify deregulated pathways in motor cortex of SALS patients,
the most informative genes (9646 genes with a standard deviation
N1.5, depicted in Fig. 1a) were subjected to pathway analysis by using
functional ontologies represented in theMetacore repository. Statistical-
ly signiﬁcant canonical pathways (108) are indicated in Supplementary
Table 5 and involve 7 different cellular processes: Apoptosis and surviv-
al, Cell adhesion, Cytoskeleton remodeling and axonal transport, Cell
cycle, Immune response, Energy metabolism and Signal transduction.
To reduce redundancy of deregulated canonical pathways and sim-
plify their comprehension, the most signiﬁcant variations implicated
in pathway analysis were summarized in Figs. 3–9 and super imposed
to statistically signiﬁcant changes of single genes.Discussion
In the following paragraphs, wewill discuss functional clusters of co-
regulated genes and pathways. As described below and represented in
Table 3, deregulation of these genes and pathways in SALS patients
was cluster speciﬁc.
Apoptosis and survival
A number of genes previously associated to apoptosis and survival
were deregulated in cortex of SALS patients (Fig. 3).
SALS2 patients showed increased expression of TNFSF6, FADD,
RIPK1 and p38 MAPK, which are involved with the triggering of the ex-
trinsic apoptotic signaling cascade. These ﬁndings are congruent with
previous data found in degenerating spinal cord and cerebral cortex
motor neurons of SOD1G93A ALS mouse model (Holasek et al., 2005;
Petri et al., 2006; Raoul et al., 2002; Raoul et al., 1999).
Sequential activation of caspases plays a central role in the execution-
phase of cell apoptosis and has been involved in motoneuron degenera-
tion in ALS (Koyama et al., 2010; Rothstein, 2009). In accordance to these
observations we found differential expression of caspase-4, 6 and 9 in
SALS2 patients. One of the ﬁnal targets of caspases is ICAD, the inhibitor
of CAD, a DNase that fragments the DNA, causing the characteristic apo-
ptotic DNA ladder (McIlroy et al., 1999; Wolf et al., 1999). In SALS2 pa-
tients we found the up regulation of ICAD and CAD.
SALS patients showed increased expression of BAD, a pro apoptotic
regulator involved in the mitochondrial intrinsic signaling pathway,
which has been extensively implicated in both ALS patients and trans-
genic SOD1G93A mice (Gonzalez de Aguilar et al., 2000; Guegan et al.,
2001; Vukosavic et al., 1999). SALS2 patients, however, showed down
regulation of pro-apoptotic BID, BCL-2, BAX, and cytochrome c, and
over expression of the anti-apoptotic protein BCL-XL. These changes
may represent an adaptive response to death stimuli and antagonize
to stress-induced apoptosis signaling.
The expression of Beclin1, a key autophagy-related gene previously
linked to ALS neurodegeneration (Erlich et al., 2006; Sasaki, 2011),
was increased in SALS patients.
Cell adhesion
Our analysis revealed differential expression of numerous genes in-
volved in cell adhesion (Fig. 4), mainly in SALS2 patients. These genes
encode for 12 integrin receptors, 3 extracellular matrix molecules (Col-
lagen IV, Laminin 1 and Fibronectin), 7 components of tight junctions
(Claudin-1, Claudin-3, Caludin-5, Jam1, Jam2, ZO-1 and ZO-2), and one
component of Gap junctions (Connexin 43). Although such a vast dereg-
ulation of integrins was previously unknown, changes in plasma Fibro-
nectin levels have previously been described in ALS patients and
signiﬁcantly correlated with the clinical progression of this disorder
(Ono et al., 2000). A progressive decrease of Collagen IV has been dem-
onstrated in serum (Ono et al., 1998) and the vascular structures of ALS
spinal cord (Miyazaki et al., 2011). High levels of Laminin 1, previously
observed in ALS spinal anterior horn, may represent a protective mea-
sure to aid neuronal survival (Wiksten et al., 2007). A signiﬁcant de-
crease of both protein and mRNA levels of tight junction components
has been described in ALS patients and animal models (Henkel et al.,
2009; Nicaise et al., 2009; Zhong et al., 2008).
In SALS2 patients we also observed the differential expression of 4 ex-
tracellularmatrixmetalloproteinases, togetherwith themetallopeptidase
inhibitor TIMP1. MMPs are a family of zinc-dependent endoproteinases
that regulate the extracellular matrix structure and play an important
role in synaptic remodeling, neuronal regeneration, and remyelination,
modulation of blood–brain and blood–cerebrospinal ﬂuid barrier perme-
ability and leukocytes invasion in neuroinﬂammatory diseases (Renaud
and Leppert, 2007). IncreasedMMPs and TIMPs have been previously re-
ported in post-mortem ALS brain tissue, as well as in plasma and
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Fig. 3. Apoptosis and survival. The apoptotic response can be activated through either the intrinsic or the extrinsic pathway, depending on the origin of the death stimuli. The extrinsic
apoptosis pathway is initiated by binding of an extracellular death ligand, such as FasL (TNFSF6) to its cell-surface death receptor FasR (CD95). Adaptor protein FADD, the serine–threonine
kinase RIPK1 and protein kinase p38MAPK transduce cell-death signals to effector caspases. The intrinsic apoptotic pathway is characterized by permeabilisation of themitochondria and
release of cytochrome c into the cytoplasm. Cytochrome c then forms amulti-protein complex known as the “apoptosome” and initiates activation of the caspase cascade through caspase
9. Sequential activation of caspases by the intrinsic or extrinsic signaling pathways plays a central role in the execution-phase of apoptosis. Bcl-2 proteins (Bcl-2, Bcl-X, Bax, Bad, Bid) play a
fundamental role in the regulation of the intrinsic pathway by controllingmitochondrial membrane permeability and the release of the pro-apoptotic factor, cytochrome c. Thermometers
labeled with (1) or (2) indicate expression levels in SALS cluster 1 and 2, respectively. Up-ward thermometers have red color and indicate up-regulated signals in SALS patients, down-
ward (blue) ones indicate down-regulated signals. Pathway objects and links are described separately in the Supplementary Fig. 3.
365E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376cerebrospinal ﬂuid (Lorenzl et al., 2003). A decrease of MMP-9 together
with an increase of MMP-1, MMP-2 and TIMP-1 values, have been con-
ﬁrmed in cerebrospinal ﬂuid of ALS patients (Niebroj-Dobosz et al.,
2010). Furthermore, deletion of MMP-9 gene in mutant SOD-1 mice ac-
celerates motor neuron disease and shortens survival (Dewil et al.,
2005). Although the role of MMPs in ALS pathogenesis is currently un-
known, altered levels of MMPs may reﬂect the degeneration process of
motor neurons and tissues remodeling (Niebroj-Dobosz et al., 2010).Fig. 2. Immunohistochemistry. Differential expression of genes implicated bymicroarraywas va
ABC) andMHC class II (HLA-DRB1, DRB3, DRB4 andDRB5)mRNAs is shown in the left/upper pa
regulation, black no change. Some of thesemRNAswere detected bymore than one probe set on
MHC class I antigens (HLA-ABC), and MHC class II antigens (HLA-DR) was performed in motor
SERPINA3was observed in reactive astrocytes of SALS1 patients. MHC class I immunoreactivity w
of SALS1patients.Weak expressionMHC class II immunoreactivitywas detected in restingmicro
was observed in activated microglial cells. Quantitative data are reported in Supplementary FigCytoskeleton remodeling and axonal transport
The cytoskeleton is critical for neuronal maintenance and plasticity,
neurite outgrowth, axonal caliber and transport. Our analysis uncovered
modiﬁcation of major components of cytoskeleton in SALS patients
(Fig. 5). Among these are genes encoding intermediate ﬁlaments pro-
teins (Nestin, GFAP, Desmin, Desmuslin, Vimentin, Peripherin, Keratins
5, 8, 14, and 18), Actin, Tubulin (alpha, beta and gamma),Myosin and alllidated by immunohistochemistry. Differential expression of SERPINA3, MHC class I (HLA-
nelwith a colormatrix. As shown in the color bar, red indicates up-regulation, green down-
themicroarray showing consistent changes. Immunohistochemistry analysis of SERPINA3,
cortex samples of control, SALS1 and SALS2 patients (n = 5/group). Immunoreactivity of
asmainly localized in endothelial cells of control patients and in activatedmicroglial cells
glial cells of control and SALS2patients, whereas in SALS1patients an increased expression
. 2.
Fig. 4. Cell adhesion. Integrins are heterodimeric cell surface adhesion receptors formed by two noncovalently associated subunits, alpha and beta. Most integrins (ITGA1, ITGA2, ITGA3,
ITGA5, ITGA6, ITGA7, ITGA8, ITGA10, ITGA11, ITGAV, ITGB1, ITGB4) recognize several ECM proteins, such as Laminin 1, Fibronectin and Collagen IV, whereas alpha-5/beta-1 integrin rec-
ognizes only Fibronectin. The ECM, integrins and the cell cytoskeleton interact at sites called focal contacts. The integrin-binding proteins Paxillin and Talin recruit Focal adhesion kinase
(FAK1) to focal contacts. Alpha-actinin is a cytoskeletal protein that crosslinks Actin in actomyosin stress ﬁbers and tethers them to focal contacts. Phosphorylation of Alpha-actinin by
FAK1 reduces the crosslinking of stress ﬁbers and prevents maturation of the focal contacts. The Actin-related protein complex (Arp2/3) nucleates new Actin ﬁlaments from the sides
of preexisting ﬁlaments. Zyxin is an Alpha-actinin and stress-ﬁber-binding protein found in mature contacts. Integrin clustering promotes FAK1 autophosphorylation, thereby creating
a binding site for c-Src. Phosphorylation of FAK1 by c-Src maximizes catalytic activity of FAK1 and creates a binding site for GRB2, thereby leading to the activation of ERK1/2. ERK2 phos-
phorylates FAK1 and decreases Paxillin binding to FAK1.Within focal contacts, FAK1-c-Src-mediated phosphorylation of Paxillin promotes ERK2 binding. ERK2-mediated phosphorylation
of Paxillin can facilitate FAK1 binding to Paxillin and enhance FAK1 activation. ERK2-mediated phosphorylation and activation of MYLK1 together with inactivation of PAK1 contribute to
cell-matrix adhesion dynamics. CRK facilitates activation of Rac1 by DOCK1. Rac1 leads to activation of MRLC and the Arp2/3 complex. Tight junctions are particularly expressed in endo-
thelia of the blood–brain barrier and are composed by transmembrane constituents (Claudin 1, Claudin 3, Claudin 5, JAM1, JAM2) and cytoplasmic proteins (ZO-1, ZO-2). Gap junctions are
clusters of transmembrane channels formed by connexins. The cytoplasmic domain of Connexin 43 binds ZO-1 and ZO-2, allowing close association between gap and tight junctions. Path-
way objects and links are described separately in the Supplementary Fig. 3.
366 E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376three neuroﬁlament subunits (NEFL, NEFM, NEFH). Most of these cyto-
skeletal proteins were up-regulated in SALS1 patients, whereas some of
them (Tubulin alpha and beta, Peripherin, NEFL, NEFM, NEFH, Dynein,Dynactin, MELC) were down-regulated in SALS2. These data are in
agreement with previous ﬁndings showing differential expression of
Peripherin, Tubulin and neuroﬁlament subunits (Kudo et al., 2010;
Fig. 5. Cytoskeleton remodeling and axonal transport. Cytoskeleton consists of three distinct, yet interconnected ﬁlament systems: microﬁlaments (actin ﬁlaments), intermediate ﬁla-
ments andmicrotubules. Microﬁlaments are the thinnest ﬁlaments of the cytoskeleton and are composed of linear polymers of actin subunits. They act as tracks for themovement ofmy-
osin molecules and are controlled by the Rho family of small GTP-binding proteins such as Rho, Rac and Cdc42. Intermediate ﬁlaments (Vimentin, Desmin, Desmusin, GFAP, Peripherin,
Nestin, NEFL, NEFM, NEFH) organize the internal tridimensional structure of the cell, anchoring organelles and serving as structural components of the nuclear lamina and sarcomeres.
Microtubules are polymers of alpha and beta tubulin and, in association to other proteins such asDynein andDynactin, are important for axonal transport. Semaphorins act as axonal guid-
ance factors. Semaphorin 3Abinds to PlexinA1 and induces repulsive responses. Ephrins and their receptor protein–tyrosine kinases regulate a variety of biological processes including the
guidance of axon growth. Pathway objects and links are described separately in the Supplementary Fig. 3.
367E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376Lederer et al., 2007; Robertson et al., 2003). Although the role of
neuroﬁlaments (NFs) in ALS is still controversial (Shaw, 2005), aberrant
accumulation of neuroﬁlaments in the cell body and proximal axons of
motor neurons is a hallmark of ALS. Deletion of NEFL subunits in the
SOD1 G85R mouse model is accompanied by preferential increase of
the NEFH and NEFM subunits in the motor neuron cell bodies and re-
duction of these subunits in the axons, with an overall signiﬁcant
delay in the onset and progression of clinical disease (Williamson
et al., 1998). Over-expression of the NEFH subunit has similar effects(Couillard-Despres et al., 1998) and has prompted the hypothesis that
NFs may act as an abundant buffer for otherwise deleterious processes,
for example offering phosphorylation sites for dysregulated intracellu-
lar kinases, or reducing the burden of axonal transport (Bruijn et al.,
1997; Julien and Beaulieu, 2000; Shaw, 2005). Decreasing the axonal
burden of neuroﬁlaments may protect motor neurons, at least in part,
by enhancing axonal transport, a hypothesis supported by the observa-
tion of defects in slow axonal transport in presymptomatic mutant
SOD1 mice (Williamson and Cleveland, 1999). Consistent with the
Fig. 6.Cell cycle. Cell cycle is characterized by four phases: G1 (gap phase 1) inwhich the cell prepares for the upcoming events of S-phase; S (synthesis phase), inwhichDNA is replicated;
G2 (gapphase 2) inwhich the cell prepares for theupcoming events ofM-phase; andM(mitosis), inwhich chromosomes are separatedover twonewnuclei. Progress in cell cycle is driven
by oscillations in the activities of cyclin-dependent kinases (CDKs), which are controlled by periodic synthesis and degradation of Cyclins, as well as by other regulators. Cyclin/CDK com-
plexes are involved in regulating different cell cycle transitions: CyclinD/CDK4 (or CDK6) for G1 progression, Cyclin E/CDK2 for theG1-S transition, Cyclin A/CDK2 for S-phase progression,
and Cyclin A/CDK1 and Cyclin B/CDK1 for entry into M-phase. Cyclin D/CDK4 (or CDK6) complexes, together with Cyclin E/CDK2 phosphorylate of the retinoblastoma family of tumor
suppressor proteins (Rb family) (Rb protein, p107 and p130), thereby liberating the E2F transcription factors. These factors are associated with DP1 and together they drive expression
of Cyclin E, Cyclin A, CDK1 andproducts that are necessary for the replication of DNA and beginning of the S phase. Checkpoint homologues (Chk1 and Chk2) inactivate by phosphorylation
cell division cycle 25A phosphatases (CDC25A, CDC25B AND CDC25C). Lack of active Cdc25A, CDC25B and CDC25C results in the accumulation of the phosphorylated (inactive) form of
CDK1, Cdk2 and Cdk4. Events controlling cell division are governed by the degradation of different regulatory proteins by the ubiquitin-dependent pathway. Phosphorylated CDC25A
may be exposed to ubiquitination by Anaphase-promoting complex (APC). CDK1 phosphorylation by Wee1 inhibits its activity during the G2-phase of the cell cycle. Phosphorylation
by PLK1 inhibits Wee1 and activates Cyclin B. Pathway objects and links are described separately in the Supplementary Fig. 3.
368 E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376view that impaired axonal transport may be involved in the degenera-
tion of motor neurons, in SALS2 patients we observed the down regula-
tion of cytoplasmic Dynein intermediate, light and heavy chains,
together with the p150Glued subunit of Dynactin (DCTN1), implicated
in retrograde transport of cargoes, such as endosomes. Mutations in
the cytoplasmic Dynein heavy chain gene have previously been found
in two mouse models, Legs at odd angles (Loa) and Cramping 1
(Cra1), with late-onset motor neuron degeneration, while mutations
of DCTN1 gene are responsible of a lower motor neuron disorder with
vocal cord paresis (Hafezparast et al., 2003; Jiang et al., 2007; Puls
et al., 2003). In addition to this, decreased expression of DCTN1 has
been reported in motor neurons of patients with SALS suggesting that
abnormalities in Dynactin may play a role in pathogenesis of ALS(Jiang et al., 2007; Puls et al., 2003). Because axon transport is a tightly
regulated process, our observation of deregulation in cargo adaptors
has the potential to signiﬁcantly disrupt transport in ALS motor
neurons.
Aberration in axon guidance may also result from differential ex-
pression of (i) Semaphorin 3A, Semaphorin 4D, and Plexin A2 in
SALS1 patients; (ii) Ephrin A, Ephrin B and their receptors, together
with their downstream signaling factors (Cdc42, Rac, RhoA) (Fig. 5).
The precise role of Semaphorins in the pathogenesis of ALS is unclear.
Increased expression of Semaphorin 3A in terminal Schwann cell of
SOD1G93A transgenic mice has previously been associated to de-
adhesion or repulsion of motor axons away from the neuromuscular
junction, eventually resulting in axonal denervation and motor neuron
Fig. 7. Immune response. Intracellular proteins are degraded by the proteasome, a multicatalytic proteinase complex composed of two sub-complexes: the 20S core complex (PSMA1,
PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB10) that carries the catalytic activity, and the 19S regulatory com-
plex (PSMC1, PSMC2, PSMC3, PSMC4, PSMC5, PSMC6, PSMD1, PSMD3, PSMD4, PSMD5, PSMD6, PSMD7, PSMD8, PSMD9, PSMD10, PSMD11, PSMD12, PSMD13, PSMD14) that receives the
polyubiquitylated substrate, removes the ubiquitin and unfolds the protein for translocation into 20S complex. The immunoproteasome is a modiﬁed proteasome, which consists of 11S
regulator (PSME1, PSME2, PSME3) andmodiﬁed 20S core. Degraded proteins are transported into endoplasmic reticulum (ER) via TAP1 transporter. MHC class I molecules are specialized
for presentation of endogenously synthesized proteins, bind ER chaperone calreticulin and then antigenic peptides.MHC class IImolecules are found on antigen-presenting cells and pres-
ent antigen derived from extracellular proteins (not cytosolic as in class I). TLR4, FCRL1, and FCRL2 aremonocyte/macrophage speciﬁc genes. Pathway objects and links are described sep-
arately in the Supplementary Fig. 3.
369E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376degeneration (De Winter et al., 2006). Indeed, Semaphorin 3A plays a
role during several stages of motor neuron circuitry formation, and its
altered expression might lead to aberrant outgrowth of corticospinal
tract ﬁbers from the cortex, inappropriate guidance of cranial motor
axons and hyperfasciculation or defasciculation of both cranial nerves
and MMC and LMC motor axons. These changes in expression might
be small and may not cause obvious defects during early life. However,
minor changes in motor neuron circuitry as a result of altered
Semaphorin 3A expression may result in motor connections, which
are more vulnerable to additional genetic or environmental changes.
Similarly to Semaphorins, Ephrins have a variety of important func-
tions including axonal outgrowth and cytoskeletal structure develop-
ment, neuronal connectivity, neuronal apoptosis, synaptic maturation
and plasticity (Huot, 2004; Klein, 2004). It is therefore plausible that
variability in such molecules could contribute to the initiation and pro-
gression of neurodegenerative diseases. Amarked increase of Ephrin A1
has previously been found in motor neurons of SALS patients (Jiang
et al., 2005) and SNPs in several Ephrin and Eph receptor genes, includ-
ing Ephrin B1, have been used to predict susceptibility, survival free and
age at onset of ALS (Lesnick et al., 2008). Our ﬁndings in ALSmotor cor-
tex supports the hypothesis that aberrant expression or function ofEphrins may induce pathological changes in motor neuron circuitry
and contribute to ALS pathogenesis (Schmidt et al., 2009).
Cell cycle
Progress in cell cycle is driven by oscillations in the activities of cyclin-
dependent kinases (CDKs), which are controlled by periodic synthesis
and degradation of Cyclins, as well as by other regulators. Alterations in
expression and cellular distribution of these proteins characterize several
human neurodegenerative diseases (Currais et al., 2009; Greene et al.,
2004; Herrup et al., 2004; Kruman, 2004; Nguyen et al., 2002; Vincent
et al., 2003; Yang and Herrup, 2007; Zhang et al., 2007). Our results
show de-regulated expression of genes encoding key regulators of G1,
S, M and G2 phases (Fig. 6).With only few exceptions, observed changes
are consistentwith a cell cycle inhibition. Dysregulation of the cyclin sys-
tem has been already proposed as a possible mechanism for ALS neuro-
degeneration, where cell death is the result of an unsuccessfully attempt
by terminally differentiated neurons to re-entry into the cell cycle
(Becker and Bonni, 2004). If so, drug inhibitors of the cell cycle might
counteract neuronal degeneration in ALS, as suggested by in vitro studies
on motor neurons (Appert-Collin et al., 2006). In SALS2 patients we also
Fig. 8. Energymetabolism. Glycolysis (upper level) converts glucose into pyruvate. During
oxidative phosphorylation (lower level) electrons are transferred from electron donors to
electron acceptors such as oxygen, in redox reactions. These redox reactions, carried out
by ﬁve main protein complexes, release energy that is used to form ATP. The energy re-
leased by electrons ﬂowing through this electron transport chain is used to transport pro-
tons across the inner mitochondrial membrane, in a process called chemiosmosis. This
generates potential energy in the form of a pH gradient and an electrical potential across
this membrane. Protons ﬂow back across the membrane and down this gradient through
ATP synthase, an enzyme that generates ATP from adenosine diphosphate (ADP), in a
phosphorylation reaction. Pathway objects and links are described separately in the Sup-
plementary Fig. 3.
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cycle checkpoint kinases (CHK1/CHK2), and the tumor suppressor gene
P53, whose increased levels have been associated with arrest of cell
cycle progression and were observed in both SOD1 transgenic mice
and ALS patients (de la Monte et al., 1998; Gonzalez de Aguilar et al.,
2000; Martin, 2000).Immune response
The immune response has been implicated in ALS and may contrib-
ute to the pathogenesis of disease or represent a response to damage
(McCombe andHenderson, 2011).While these positive and negative ef-
fects are beginning to be appreciated, their potential as drug targets is
being explored (Calvo et al., 2010; Holmoy, 2008; Moisse and Strong,
2006). Reactive microglia and inﬂammatory processes coincide with
ALS onset and disease progression in SOD1 transgenic mice (Hall et al.,
1998), and postmortem examinations of neural tissues in ALS patients
show both innate and adaptive immunity activation (Barbeito et al.,
2010; Sta et al., 2011).
In our study we observed the differential expression of an exten-
sive number of immune-related genes in the cortex of SALS patients
(Fig. 7). Correlation of these with a compendium of immune related
genes (Abbas et al., 2005) provided a qualitative assessment of
the preponderance of immune cell types present (Supplementary
Table 6). The 1188 immune related genes in SALS patients were spe-
ciﬁc for the presence of genes related to both the lymphoid and my-
eloid (such as macrophages and dendritic cells) lineages. Among
these immune-cell speciﬁc genes is TLR4, a marker of monocyte/
macrophage activation previously observed in spinal cords of ALS
patients (Casula et al., 2011).
In SALS patients we observed deregulated expression of several
genes encoding proteins involved with antigen processing and presen-
tation. Most of these genes were increased in SALS1 and reduced in
SALS2 patients. Proteins involved in antigen processing belong to the
26S proteasome/20S immunoproteasome, proteasome 19S regulator
and immunoproteosome 11S regulator (Fig. 7). Increased expression
of serpin peptidase inhibitor, clade A, member 3 (SERPINA3) wasmain-
ly observed in SALS1 patients (Fig. 2). The protein encoded by this gene
is an acute phase reactant protein considered an important link be-
tween the immune/inﬂammatory response and proteosomal turnover.
Up-regulation of SERPINA3 in ALS pathology was previously found in
several mouse models and human studies (Saris et al., 2013).
Proteins involved in antigen presentation includemajor histocompat-
ibility complex (MHC) class Imolecules (HLA-A,HLA-B, HLA-C), TAP1 and
calreticulin. The proteasome system is the major intracellular proteolytic
mechanism controlling the degradation of misfolded/abnormal proteins
and their accumulation into damagedneurons represents a commonhall-
mark in ALS. Deregulation of the constitutive and inducible proteasome
subunitsmay not only inﬂuence the ubiquitin-mediated protein degrada-
tion but also lead to generation of peptides that can be used by MHC I
molecules for antigen presentation to the immune system, providing an
interesting connection between the immune-responses and proteasome
function (Bendotti et al., 2012). In addition to MHC class I, we found the
deregulated expression of a series of genes, encoding MHC class II mole-
cules, which are found on antigen-presenting cells and present antigen
derived from extracellular proteins (Figs. 2 and 7). These MHC class II
molecules were up-regulated in SALS1 patients and down-regulated in
SALS2.
Up-regulation of several cytokines and IFNβ was observed in SALS2
patients. Although the pathogenic role of cytokines in ALS is still un-
known, previous studies have associated their abnormal expression to
the clinical status (Moreau et al., 2005; Rentzos et al., 2010; Shi et al.,
2007). Similarly, enhanced expression of IFNβ has been demonstrated
in spinal cord of SOD1 mice and may represent an early response to
pathological changes in ALS (Wang et al., 2011).
Fig. 9. Signal transduction. Several genes encoding ligands and receptors involved in signal transductionwere differentially expressed in SALS patients. Signaling pathways include primary
(such as Adenylate cyclase, Phospholipase C or tyrosine kinase receptors) and secondary (such as Ca2+ release, PKC or protein kinase cascades) effectors that are regulated at multiple
levels with different mechanisms (such as binding or phosphorylation). Pathway objects and links are described separately in the Supplementary Fig. 3.
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Genes implicated in energy metabolism included those involved in
glycolysis and mitochondrial oxidative phosphorylation (Fig. 8).
Among the ﬁrst are those encoding two rate limiting step enzymes, 6-
phosphofructokinase (PFKM and PFKP) and pyruvate kinase (KPYR
and PKM2), and MDH1, which we previously linked to ALS pathology
(Lederer et al., 2007). These genes were mainly down-regulated inSALS2 patients. In the same patients we observed the coordinated de-
crease of several genes encoding proteins involved in the oxidative
phosphorylation pathway, the major cellular energy supply system. In
contrast, a limited but signiﬁcant number (8) of these genes were in-
creased in SALS1. Down-regulated genes in SALS2 encodeproteins of re-
spiratory complex I (36/46 subunits), II (SDHB and SDHD), III (7/11
subunits), IV (6/13 subunits) and V (10/14 subunits of the catalytic
and membrane proton channel of ATP synthase) (Fig. 8). An increase
Table 3
Pathways differentially deregulated in cluster SALS patients.
Red boxes represent cellular processes mainly up-regulated, green bars down-regulated,
red/green bars indicate signal pathways both up- and down-regulated, gray bars indicate
no signiﬁcant change when compared to controls.
372 E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376of complex I (Bowling et al., 1993), and a deﬁciency of complex IV was
previously found in post mortem ALS tissue (Borthwick et al., 1999).
This apparent discrepancy may be explained by the opposite behavior
of SALS patients found in the present study (increase of complex I in
cluster 1, and decrease of complex IV in both clusters). Mitochondrial
dysfunction (mainly from morphological evidence) and disruption of
energy metabolism have been proposed to play a major role in ALS pa-
thology and treatments designed to improve respiratory chain function
may ameliorate the progression of this disorder (Cozzolino and Carri,
2012; Lee et al., 2009; Pizzuti and Petrucci, 2011).
Signal transduction
Neuropeptides and receptors
The expression of genes encoding Adiponectin and its receptors R1
and R2 (Fig. 9) were down-regulated in SALS patients. Beyond their pe-
ripheral effects on fat metabolism and insulin sensitivity, Adiponectinand its receptors are expressed in brain (Brown et al., 2007; Wilkinson
et al., 2007), where they regulate neuronal excitability (Hoyda and
Ferguson, 2010) and exert protective effects against neurotoxicity
(Chan et al., 2012; Jeon et al., 2009; Qiu et al., 2011). In SALS2 patients
we observed the up-regulation of another adipokine, Leptin, which is
endowed with neurotrophic and neuroprotective properties (Tang,
2008). Induction of Leptin in brain (microglia/macrophage cells) has
been described in ischemic cerebral cortex, suggesting the possibility
that this peptidemay act as an endogenousmediator of neuroprotection
(Valerio et al., 2009). Decreased expression of PTCH1 is in agreement
with the neuroprotective effects of Sonic hedgehog (Shh) signaling in
SODmice (Peterson andTurnbull, 2012). Three genes encodingproteins
implicated in neurite outgrowth and ALS pathology, Myelin-associated
glycoprotein (MAG), Reticulon-4 and its receptor were down-
regulated in SALS2 patients. Anti-MAG antibodies have been observed
in ALS patients (Antoine et al., 1993), whereas a number of studies
have already implicated Reticulon-4 in ALS pathology (Teng and Tang,
2008), demonstrating a protective effect against ALS-like neurodegen-
eration (Yang et al., 2009).
Several trophic factors and their receptors were differentially
expressed in SALS cortex. Among them are all the epidermal growth fac-
tor receptors and some of their ligands. Decreased levels of EGFwere pre-
viously observed in liquor of ALS patients (Cieslak et al., 1986; Klimek
et al., 1990) and treatment with this growth factor has been successfully
evaluated in ALS animal models (Del Barco et al., 2011; Ohta et al., 2006).
Consistent with our observations are reports showing decreased levels of
Neuregulin in cerebral spinal ﬂuid of ALS patients (Pankonin et al., 2009)
and aberrant Neuregulin signaling in ALS patients and in SOD1 mice
(Song et al., 2012). In SALS cortex samples we also observed the altered
expression of genes encoding three ﬁbroblast growth factor receptors
and seven of their ligands. Increased FGF1 might activate astrocytes,
which could in turn initiate motor neuron apoptosis in ALS (Cassina
et al., 2005). Reduced expression of FGF9 is consistent with its role as
an autocrine or paracrine survival factor for motoneurons (Kanda et al.,
1999). Altered expression of genes encoding one member of the
neurotrophin family of growth factors (BDNF) and their receptors
(TrkA, TrkB, TrkC, NGFR) were observed in SALS patients. These data are
in agreementwith an extensive amount of data supporting their implica-
tion in human (Koliatsos et al., 1993; Seeburger and Springer, 1993) and
animal models (Liao et al., 2012; Yanpallewar et al., 2012) of ALS pathol-
ogy. The expression of vascular endothelial growth factors (VEGF-A,
VEGF-B, VEGF-C, VEGF-D) and their receptors (VEGF-R1, VEGF-R2,
Neuropilin 1, Neuropilin 2) was mainly down-regulated in SALS2 pa-
tients. There is extensive evidence linking this family of ligands and re-
ceptors to ALS pathology (Brockington et al., 2006; Lambrechts et al.,
2003; Lunn et al., 2009; Nagara et al., 2013; Spliet et al., 2004) and treat-
mentwithVEGFwas found to prevent neuronal death in differentmodels
of ALS (Hwang et al., 2009; Shimazawa et al., 2010; Storkebaum et al.,
2005; Tovar-y-Romo and Tapia, 2012; Wang et al., 2007; Zheng et al.,
2004).
Down regulation of hepatocyte growth factor (HGF), one of themost
potent survival-promoting factors for motor neurons with potential
therapeutic effects on ALS (Ishigaki et al., 2007; Kadoyama et al., 2007;
Sun et al., 2002) was observed in SALS2. Decreased expression of
Thyrotropin-releasing hormone receptor in SALS2 patients supports
previous studies showing a reduction of this receptor in spinal cord of
ALS patients (Manaker et al., 1988) and may explain the conﬂicting re-
sults obtained by TRH therapy (Brooks, 1989; Congia et al., 1991).
The expression of several genes encoding G-protein coupled recep-
tors and/or their ligands is altered in SALS patients. Some of these, such
as the Muscarinic acetylcholine receptors (Gillberg and Aquilonius,
1985; Whitehouse et al., 1983), the endothelin-1 and its receptor B,
have been previously associated to ALS pathology (Lederer et al.,
2007). Differential expression of Angiotensin II and its type-1 receptor
may be linked to the altered levels of Angiotensin II found in liquor of
ALS patients (Kawajiri et al., 2009), whereas that of Leukemia inhibitory
Fig. 10. Genes previously associated to FALS. To analyze changes in gene expression in the context of genes previously associated to FALS, we built up a pathwaywith 53 of these genes. A
majority of these genes (37/53) were signiﬁcantly deregulated in the cortex of SALS patients. Pathway objects and links are described separately in the Supplementary Fig. 3.
373E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376factor (LIF) and its receptor are consistentwith a study proposing LIF as a
modiﬁer gene in ALS (Giess et al., 2000). The up regulation of IGF1 recep-
tor is in agreement with previous studies (Chung et al., 2003; Wilczak
et al., 2003), whereas that of purinergic receptor P2Y2 supports the
role for P2 receptor signaling in ALS (D'Ambrosi et al., 2009).
Ion homeostasis
A number of genes encoding proteins regulation ion homeostasis
were deregulated in motor cortex of SALS patients (Fig. 9). Decreased
expression of CACNA1C is consistent with the presence of immunoglob-
ulins against this L-type voltage-gated calcium channels in ALS patients,
which correlate with disease progression and exert neurototoxicity
(Kimura et al., 1994; Smith et al., 1994). Down regulation of three sub-
units of the N-methyl-D-aspartate (NMDA) receptor (GRIN1, GRIN2A,
GRIN2D) in SALS2 patients is in agreement with previous studies in an-
imal models (Spalloni et al., 2011) and with a large literature indicating
that a dysfunction of these ligand-gated cation channels may be an un-
derlyingmolecularmechanism in ALS (Spalloni et al., 2013). Three sub-
units of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate
(AMPA) glutamate receptor were differentially expressed in SALS pa-
tients: GRIA1 increased in cluster 1 patients, whereas GRIA2 and
GRIA3 were reduced in SALS2. Similar changes in expression of GRIA1
and GRIA2 have been reported in SOD1 mice (Spalloni et al., 2006),
whereas in human a defect in the editing of the messenger RNA
encoding GRIA2 has been previously reported (Kawahara et al., 2004).
AMPA receptors lacking the GRIA2 subunit are permeable to Ca2+ andthe entrance of this cationmight be responsible for the selective vulner-
ability of spinal motoneurons in ALS. Down regulation of six subunits of
the gamma-aminobutyric acid (GABA) A receptor were found in SALS2
patients. Although impaired GABAergic signaling in ALS pathology has
been previously proposed, little is known about its receptor composi-
tion. The few studies present in the literature, conﬁrm the reduced ex-
pression of the alpha1 subunit in ALS patients (Petri et al., 2003).
Genes previously linked to ALS
As described in the introduction, a large number of genes have been
associated to FALS and available in online databases, such as OMIM,
ALSGene (Lill et al., 2011), ALS mutation database (Yoshida et al.,
2010), and ALSoD (Abel et al., 2012). To analyze changes in gene expres-
sion in the context of these genes, we built up a pathway with 53 of
these genes (Fig. 10). A majority of these genes (37/53) were differen-
tially expressed in the cortex of SALS patients (some are up-regulated
in SALS1, whereas most are down-regulated in SALS2). Deregulation of
genes whose mutation has been previously associated to FALS provides
a common pathogenic link between familiar and sporadic ALS that has
not been previously appreciated.
Conclusion
ALS is a rare neurodegenerative disease affectingmotor neurons. Al-
though postmortem brain tissue reveals the end-stage pathogenic
374 E. Aronica et al. / Neurobiology of Disease 74 (2015) 359–376mechanisms of this disorder, its use provides indispensable elements
that cannot be obtained by other approaches or on a living person. In
the last few years, a number of transcriptome studies have started to de-
cipher genes and pathways involved in ALS pathogenesis but were re-
stricted to a limited number of postmortem samples (≤11 motor
cortex, and 14 spinal cord) (Cox et al., 2010; Dangond et al., 2004;
Jiang et al., 2005; Lederer et al., 2007; Malaspina et al., 2001; Offen
et al., 2009; Rabin et al., 2010;Wang et al., 2006). To uncover the entire
spectrum of genes and pathways involved in ALS pathology we have
now screened a large number of well-characterized (clinically and
neuropathologically) motor cortex specimens from control and SALS
patients. In addition to conﬁrming the differential expression of 83% of
those genes (Supplementary Table 7) that were reported in our previ-
ous study (Lederer et al., 2007), the results obtained in a larger cohort
show that gene expression proﬁles of motor cortex samples can differ-
entiate SALS pathology from controls and clearly distinguish two SALS
groups, each associated to deregulation of different genes and path-
ways. Although the present study represents the largest andmost com-
prehensive transcriptome study of SALS brains to date, the sample size
lacked sufﬁcient power to associate clinical characteristics of patients
with cluster assignment. While this functional association will require
a much larger sample size, the present study proposes the use of unsu-
pervised hierarchical clustering as an objective method to identify dif-
ferent SALS subtypes and reveal new clues to the pathogenesis and
potential therapeutic targets. Molecular classiﬁcation based on gene ex-
pression is revolutionizing theway different pathologies, such as cancer,
are diagnosed and opening theway to personalized therapies. Similarly,
a molecular taxonomy of SALS patients may reveal etio-pathogenic
mechanisms that may have been masked by considering SALS patholo-
gy as a single entity andhelp orienting them topersonalized treatments.
The altered networks of biological molecules in SALS provide a
number of potential therapeutic targets (Supplementary Table 8),
which could be used to interfere with ALS pathogenesis. In view of
the genomic heterogeneity of sporadic ALS, we may rethink our
strategies for drug development, targeting ALS pathogenesis with
personalized drugs and as a system rather than at the level of the sin-
gle protein molecule.
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